Short communicationManagement of benzodiazepine-resistant alcohol withdrawal across a healthcare system: Benzodiazepine dose-escalation with or without propofol☆
Introduction
Alcohol withdrawal syndrome (AWS) occurs in patients due to cessation of alcohol, which is an agonist of γ-aminobutyric acid (GABA), an inhibitory neurotransmitter (Bayard et al., 2004). Alcohol-induced alterations of GABA and upregulation of the excitatory neurotransmitter N-methyl-d-aspartase (NMDA) results in associated withdrawal symptoms (Sarff and Gold, 2010). Benzodiazepines (BZDs) often serve as first-line therapy as they target the GABA-A receptor, which mediates the primary GABA effects of ethanol in the body (Brathen et al., 2005, Mayo-Smith et al., 2004, Nakagawa and Iwasaki, 1995). Despite escalating doses of BZDs, a subset of patients do not adequately respond (Gold et al., 2007, Hack et al., 2006). Benzodiazepine-resistant alcohol withdrawal (RAW) is defined as the requirement of ≥40 mg of diazepam (or equivalent) administered within one hour (Hack et al., 2006).
The use of agents that target another binding site of the GABA receptor or other modes of action may be beneficial in RAW patients (Liang et al., 2009, Radel and Goldman, 2001, Wong et al., 2015). Propofol has GABA-agonist activity at an alternative GABA receptor binding site, antagonizes NMDA, and has a relatively short duration of action allowing for ease in titration (Liang et al., 2009). Studies evaluating propofol for management of AWS initiated propofol after patients received significant amounts of BZDs, with variable effectiveness ranging from no benefit to effective management of agitation (Coomes and Smith, 1997, Hughes et al., 2014, Lizotte et al., 2014, Lorentzen et al., 2014, Sohraby et al., 2014). Other adjunct agents were allowed in these studies, including antipsychotics and phenobarbital, which may confound the effects of propofol alone on studied outcomes.
The purpose of this study is to describe the clinical characteristics of dose escalation of BZDs alone (BZDO) compared to BZDs plus propofol (PRO) in a RAW population, as evidence currently is lacking for the addition of only propofol without other adjunctive agents to BZDs for management of RAW. The primary endpoint was the time to resolution of AWS, with secondary endpoints including safety outcomes associated with medication use.
Section snippets
Patient population and setting
A retrospective cohort of adult patients were identified via International Classification of Diseases, Ninth Revision (ICD-9) codes with severe alcohol withdrawal (291.0, 291.2, 291.3, 291.81, 303.01, 303.91) from January, 2009 to March, 2012 in the University of Pittsburgh Medical Center health system.
From this population, a chart review using an electronic health record (Cerner Powerchart®, Kansas City, MO) was conducted to identify patients who met RAW criteria (requirement of ≥40 mg of
Patients
Of 1083 records reviewed of patients with ICD-9 codes for severe alcohol withdrawal, a total of 66 (6.1%) patients met eligibility. Patients were excluded due to lack of BZD-qualifying dosing for RAW (n = 834), receiving their RAW-designating dose for other indications, (n = 65), use of additional adjunctive agents for management of AWS (n = 106), or lack of BZD dose-escalation in the BZDO group (n = 12). Baseline demographics are provided in Table 1. There were differences at baseline between the
Discussion
In this retrospective description of patients with RAW, the addition of propofol to BZDs was associated with decreased short-term BZD requirements, consistent with the literature (Sohraby et al., 2014). We found that there was a significant increase in clinical care, as shown by worsening clinical outcomes and increased need for airway protection in these patients. This association may be reflective of indication bias in the PRO group as propofol, given its respiratory depressant effects,
Role of funding source
Nothing declared.
Contributors
Drs. Benedict and Kane-Gill have been supported by an investigator-initiated grant from Hospira, Inc. within the past five years. Study conception and design: Benedict, Kane-Gill, Lohr, Wong. Acquisition of data: Lohr, Wong. Analysis and interpretation of data: Benedict, Kane-Gill, Lohr, Pizon, Wong. Drafting of manuscript: Benedict, Kane-Gill, Lohr, Pizon, Wong. Critical revision: Benedict, Kane-Gill, Lohr, Pizon, Wong. All authors have read and approve of the submission to Drug and Alcohol
Conflict of interest
No conflict declared.
References (23)
- et al.
Successful use of propofol in refractory delirium tremens
Ann. Emerg. Med.
(1997) - et al.
Propofol for benzodiazepine-refractory alcohol withdrawal in a non-mechanically ventilated patient
Am. J. Emerg. Med.
(2014) - et al.
Involvement of benzodiazepine/GABA-A receptor complex in ethanol-induced state-dependent learning in rats
Brain Res.
(1995) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia
Am. J. Respir. Crit. Care Med.
(2005)- et al.
Alcohol withdrawal syndrome
Am. Family Phys.
(2004) - et al.
EFNS guideline on the diagnosis and management of alcohol-related seizures: report of an EFNS task force
Eur. J. Neurol.
(2005) - et al.
Motor Activity Assessment Scale: a valid and reliable sedation scale for use with mechanically ventilated patients in an adult surgical intensive care unit
Crit. Care Med.
(1999) - et al.
Childhood disorders
- et al.
A strategy of escalating doses of benzodiazepines and phenobarbital administration reduces the need for mechanical ventilation in delirium tremens
Crit. Care Med.
(2007) - et al.
Anxiety disorders
Resistant alcohol withdrawal: does an unexpectedly large sedative requirement identify these patients early?
J. Med. Toxicol.
Cited by (24)
Predictors of resistant alcohol withdrawal (RAW): A retrospective case-control study
2018, Drug and Alcohol DependenceCitation Excerpt :However, we attempted to minimize the impact of this limitation with our exclusion criteria. Medication management including BZD dosing for the RAW and nRAW groups was not reported in this risk-factor analysis as we have previously published those findings (Wong et al., 2015a, b). Finally, exclusion of subsequent hospitalizations for patients meeting study inclusion with multiple admissions altered our initial 2:1 nRAW/RAW randomization ratio leading to a greater number of nRAW patients included in the final analysis (∼2.3/1).
The emergency medicine management of severe alcohol withdrawal
2017, American Journal of Emergency MedicineCitation Excerpt :Propofol was efficacious in 12 of 15 patients, with 3 needing further treatment [45]. If the patient reaches the point of requiring intubation due to treatment resistant DT, intubation should be completed with propofol induction [5-9,40-46]. Propofol induction and intubation will require further critical management in the ICU [44-47].
Palladium-benzodiazepine derivatives as promising metallodrugs for the development of antiepileptic therapies
2016, Journal of Inorganic BiochemistryCitation Excerpt :Thus, DZP–palladium(II) complexes seems to act at the same receptor of DZP, but it is possibly that acting on different sites of the same GABAA receptor. This possibility could bring the hypothesis that DZP–palladium(II) complexes do not produce some side-effects or pharmacoresistant, for example, which are common in the DZP treatment [50,51]. It would be interesting to double-check this possibility in future studies.
GHB: a life-threatening drug complications and outcome of GHB detoxification treatment—an observational clinical study
2023, Addiction Science and Clinical PracticePractice Patterns in the Diagnosis and Management of Alcohol Withdrawal Syndrome in Indian Intensive Care Units
2023, Indian Journal of Critical Care MedicineAdjuvant dexmedetomidine in treatment of alcohol withdrawal delirium: Case series
2023, Medical Journal of Dr. D.Y. Patil Vidyapeeth
- ☆
Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org/10.1016/j.drugalcdep.2015.07.005